Alex Denner is out at Biogen as new CEO Viehbacher crafts a fresh board with Susan Langer, Caroline Dorsa

John Carroll

Editor & Founder

Biogen’s big top-level shakeup continued Monday evening with news that Alex Denner — first elected to the board back in 2009 when he spearheaded Carl Icahn …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alex Denner is out at Biogen as new CEO Viehbacher crafts a fresh board with Susan Langer, Caroline Dorsa

John Carroll

Editor & Founder

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New Flagship startup aims to trailblaze ‘AI science factories’

Beam shares promising first clinical data on gene editing treatment for a lung and liver disease

Exclusive: FDA blocks drug and device reviewers from taking HHS' buyout offer

Exclusive: Daiichi Sankyo, Johnson & Johnson partner with RNA delivery startup Nosis Bio

J&J, Protagonist outline first IBD win for oral IL-23 with $5B+ sales potential

Obesity drug development—still room to grow

Alex Den­ner is out at Bio­gen as new CEO Viehbach­er crafts a fresh board with Su­san Langer, Car­o­line Dor­sa

Editor & Founder

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Alex Denner is out at Biogen as new CEO Viehbacher crafts a fresh board with Susan Langer, Caroline Dorsa